Locations
California, MD, USA
industry
Biotechnology · DeepTech · Health
Size
1 - 10 employees
Stage
Seed
founded in
2021
Vironexis Biotherapeutics is pioneering AAV-delivered T-cell immunotherapy to transform cancer treatment. Their Trans Join™ AAV Gene Therapy Platform offers off-the-shelf, single-dose therapies that enhance safety and efficacy while addressing the limitations of existing treatments like CAR-T. With a pipeline of over 10 product candidates targeting various cancers, including blood-based cancers and solid tumors, Vironexis aims to provide scalable and practical solutions for patients. The company has achieved significant milestones, including FDA IND clearance for its lead candidate, VNX-101, and is positioned to revolutionize the immunotherapy landscape.
Something looks off?